Literature DB >> 31079596

Drawing from the Theory of Planned Behaviour to examine pre-exposure prophylaxis uptake intentions among heterosexuals in high HIV prevalence neighbourhoods in Philadelphia, Pennsylvania, USA: an observational study.

Alexis Roth1, Marisa Felsher2, Nguyen Tran3, Scarlett Bellamy3, Ana Martinez-Donate2, Douglas Krakower4, Zsofia Szep5.   

Abstract

Background Research surrounding attitudes and intentions concerning pre-exposure prophylaxis (PrEP) among at-risk heterosexuals, women and ethnic and racial minorities is needed to inform programs to scale this effective HIV prevention intervention among these populations.
METHODS: The study sample includes 192 HIV-negative heterosexuals recruited from HIV testing sites operating in high HIV prevalence neighbourhoods in a mid-Atlantic city. Participants received brief educational sessions on PrEP and completed a self-administered survey assessing sociodemographic factors, HIV risk behaviours and theoretical determinants of PrEP uptake, based on the Theory of Planned Behaviour.
RESULTS: Participants were majority persons of colour (86%), with a median age of 43 years. Compared with Whites, a higher percentage of Black and Brown persons had more than five sex partners (75.0%), used condoms inconsistently (85.6%) and engaged in transactional sex (84.4%). Most expressed positive PrEP attitudes and indicated intention to adopt PrEP, especially if recommended by their doctor. In a multivariable model, willingness to take PrEP if suggested by a healthcare provider (aOR: 4.17; 95% CI: 1.42-12.24) and willingness to take PrEP even if it caused side-effects (aOR: 1.98; 95% CI: 1.01-3.90) were both associated with greater PrEP adoption intentions.
CONCLUSIONS: A diverse at-risk population was identified through community-based HIV testing. Low perceived HIV risk, as well as PrEP-related attitudes, subjective norms and perceived behavioural control were associated with PrEP use intentions. These factors are potential targets for interventions to increase PrEP adoption among diverse heterosexual samples.

Entities:  

Mesh:

Year:  2019        PMID: 31079596     DOI: 10.1071/SH18081

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  6 in total

1.  Understanding Influences on Intention to Use Pre-exposure Prophylaxis (PrEP) Among African American Young Adults.

Authors:  Suur D Ayangeakaa; Jelani Kerr; Ryan Combs; Lesley Harris; Jeanelle Sears; Kimberly Parker; Emma Sterrett-Hong
Journal:  J Racial Ethn Health Disparities       Date:  2022-03-15

2.  Examining Factors that Impact Intentions to Use Pre-Exposure Prophylaxis Among African-American Young Adults.

Authors:  Jelani Kerr; Ryan Combs; Suur Ayangeakaa; Lesley Harris; Nana Bullock; Emma Sterrett-Hong; Kimberly Parker
Journal:  Arch Sex Behav       Date:  2021-10-12

3.  Are Sexual Minority Stressors Associated with Young Men who Have Sex with Men's (YMSM) Level of Engagement in PrEP?

Authors:  Steven Meanley; Cristian Chandler; Jessica Jaiswal; Dalmacio D Flores; Robin Stevens; Daniel Connochie; José A Bauermeister
Journal:  Behav Med       Date:  2020-05-13       Impact factor: 3.104

4.  Intention to initiate and uptake of PrEP among women who injects drugs in a demonstration project: an application of the theory of planned behavior.

Authors:  Nguyen K Tran; Marisa Felsher; Barbara Van Der Pol; Scarlett L Bellamy; Jade McKnight; Alexis M Roth
Journal:  AIDS Care       Date:  2021-01-23

5.  Uptake and willingness to use PrEP among Chinese gay, bisexual and other men who have sex with men with experience of sexualized drug use in the past year.

Authors:  Zixin Wang; Phoenix K H Mo; Mary Ip; Yuan Fang; Joseph T F Lau
Journal:  BMC Infect Dis       Date:  2020-04-22       Impact factor: 3.090

6.  Preexposure prophylaxis strategies for African-American women affected by mass incarceration.

Authors:  Joëlla W Adams; Maria R Khan; S E Bessey; Samuel R Friedman; James M McMahon; Mark N Lurie; Sandro Galea; Brandon D L Marshall
Journal:  AIDS       Date:  2021-03-01       Impact factor: 4.632

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.